November 11, 2026

  UPFRONT BRIEFING

Beam just turned base editing into a filing story: risto-cel cleared BEACON's bar of 12 straight months free of severe pain crises, and a BLA could land by year-end. The catch is what Beam left out (no response rate, thin safety detail), which is why the stock wobbled on a win.

PepGen nearly doubled on DM1 splicing data and promptly launched a $125M raise, while FDA cleared Merck KGaA and Abbisko's pimicotinib in TGCT after the bell. BIO-Europe wraps in Cologne today, and Summit's ivonescimab PDUFA lands Saturday.

TAPE ACTION

  • Healthcare edged up 0.3% while biotech lagged: XBI (1.2%), NBI (0.9%), BBC (0.2%). Single names did the talking: PepGen +92.9% on pre-open DM1 data, Beam down as much as 10% intraday after its pivotal readout, Legend Biotech ~(17%) intraday after Q3, ImmunityBio ~(20%).

  • October CPI ran hot at 8:30 ET: headline +0.4% m/m vs +0.3% expected, core +0.3% vs +0.2% (no y/y, shutdown gap). Waller floated 50bp and CME moved to ~88% for a 25bp December hike; 10Y +10bp to 4.98%, 2Y +17bp. Nvidia (5.5%) on its board's Huang probe dragged tech (1.2%); NDX (0.6%), S&P (0.4%), RUT (0.7%), Dow (0.3%).

THE BIG 3

1️⃣ — Beam's risto-cel clears its pivotal sickle cell bar, BLA by year-end

  • Risto-cel, Beam's base-edited sickle cell therapy, met BEACON's primary endpoint of at least 12 consecutive months free of severe vaso-occlusive crises in 31 evaluable patients (49 dosed as of 20 Oct), and Beam plans a BLA as early as year-end 2026.

  • Why it matters: BEACON's interim read covered 31 of 49 dosed patients, and Beam met the primary on independently adjudicated freedom from severe VOCs without disclosing the share who got there. H.C. Wainwright flagged that gap and the thin safety detail, which is why the stock fell as much as 10% on a pivotal win. The case against Casgevy is operational: RBC points to a shorter manufacturing run and fewer mobilisation cycles, in a market where Vertex booked $219M of Casgevy sales in nine months and Lyfgenia's owner sold itself. Busulfan conditioning stays, along with the 2024 death Beam tied to chemotherapy. Cash of $1.04B funds a year-end BLA, the first for a base editor, and the updated data Beam has promised before then.

  • Source: Endpoints

2️⃣ — FDA clears Merck KGaA and Abbisko's pimicotinib in TGCT

  • FDA approved Pimjetmi (pimicotinib), Abbisko's oral CSF-1R inhibitor licensed to Merck KGaA, for adults with symptomatic tenosynovial giant cell tumor where surgery risks worsening function; the decision crossed after Tuesday's close.

  • Why it matters: MANEUVER gave pimicotinib a 56% week-25 response rate versus 3% on placebo, and 77% of responders held benefit through a further 12 months. It is the third CSF-1R inhibitor in TGCT, behind Daiichi Sankyo's Turalio, whose liver-injury boxed warning and REMS have capped use, and Ono/Deciphera's Romvimza, which has the clean-label pitch to itself today. Merck KGaA licensed global rights in December 2023 for $70M upfront; Abbisko now collects a first-sale milestone plus double-digit royalties. FDA reviewed it under Project Orbis after approvals in China, Canada and Switzerland. TGCT is a small market, so the bigger read is a China-originated asset clearing FDA while Treasury's draft COINS rule leaves straight licences outside its scope.

3️⃣ — PepGen nearly doubles on DM1 splicing data, then raises

  • PGN-EDODM1, PepGen's oligonucleotide for myotonic dystrophy type 1, averaged 46.5% splicing correction in six patients at 10 mg/kg in the Phase 2 FREEDOM2 study, with improvements in myotonia and in measures of mobility and strength.

  • Why it matters: Six patients on 10 mg/kg averaged 46.5% splicing correction after four monthly doses, four topped 50%, and myotonia improved on a hand-relaxation test at 13 weeks. Leerink's Schwartz puts that ahead of Novartis' del-desiran and Dyne's z-basivarsen, with the usual cross-trial caveat; del-desiran's pivotal failure is why the functional signal matters more than splicing alone. PEPG closed up 92.9% at $4.61, and PepGen launched a $125M stock offering that evening through Leerink, Stifel and Guggenheim. The US partial clinical hold tied to animal findings still stands, so there is no US dosing yet, and higher-dose data are due 1H27. Nausea and a transient post-dose rise in urinary protein are the safety items to watch.

  • Source: STAT

EVERYTHING ELSE THAT BROKE

  • Mirum's brelovitug hit the AZURE-4 Phase 3 primary in 113 treatment-naïve HDV patients: 59% (300 mg weekly) and 44% (900 mg monthly) reached virologic response plus ALT normalization at week 24 vs 0% on delayed treatment; US filing 2027. — Endpoints

  • ImmunityBio said Anktiva plus BCG met the QUILT-2.005 Cohort A primary endpoint in BCG-naïve NMIBC but gave no effect size; sBLA planned for Q4, and shares fell ~20% alongside Q3 Anktiva sales of $48.7M. — Fierce Pharma

  • Legend Biotech's Q3 Carvykti sales reached ~$710M (+36% y/y; US +19%, ex-US +86%) and Legend booked $51.7M net income; shares fell ~17% intraday. — Legend 6-K

  • J&J's Caplyta logged a second Phase 3 win in bipolar mania, setting up a label-expansion filing. — Fierce Pharma

  • Coherus Oncology is cutting 30% of its workforce again as it narrows its CCR8 antibody programme to esophageal cancer. — Fierce Biotech

  • AbCellera dropped its OX40 programme, the latest developer to walk away from the target. — Fierce Biotech

  • Congressional Democrats asked drugmakers with Trump MFN pricing deals to disclose the unredacted agreements, their first oversight move since the midterms. — Endpoints

DEAL FLOW

Track the Deals Shaping Biotech

Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.

M&A / BD&L

  • AstraZeneca acquired Omniose, its bacterial-vaccine research partner, adding a single-cell enzymatic bioconjugation platform for polysaccharide conjugate vaccines; terms undisclosed. — Fierce Biotech

  • ProBio (GenScript's CRDMO) licensed AbTis (Dong-A ST) exclusive global rights to a discovery-stage antibody against an undisclosed oncology target, for bispecific ADCs; upfront, milestones and royalties undisclosed. — PR

VC / PRIVATE FINANCINGS

  • No notable private biotech financings since yesterday's edition.

IPO / FOLLOW-ON

  • Prime Medicine (PRME) priced $125M: 35,714,286 shares at $3.50, plus a 5,357,142-share option; Jefferies, TD Cowen, Goldman Sachs; close ~12 Nov. — GlobeNewswire

  • PepGen (PEPG) launched a $125M offering of common stock and pre-funded warrants after closing at $4.61 (+92.9%) on its DM1 data; Leerink, Stifel, Guggenheim. — SEC 424B5

ACADEMIC CORNER

  • Next-generation KRAS G12C inhibitor improves survival in lung cancer. — Nature Medicine

  • A novel candidate biomarker for detecting premalignant and early ovarian cancer. — Nature Medicine

  • Blood-based RNA biomarker for the early detection of ovarian cancer. — Nature Medicine

Know someone who'd like this?

Forward it along. It takes ten seconds and means a lot to us.

May your pivotal wins stay pivotal and your PDUFA dates land on a weekday.

— The BioBucks Team